These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33808455)

  • 1. Biologics for Psoriasis during the COVID-19 Pandemic.
    Kamiya K; Komine M; Ohtsuki M
    J Clin Med; 2021 Mar; 10(7):. PubMed ID: 33808455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologics for Psoriasis During the COVID-19 Pandemic.
    Zeng H; Wang S; Chen L; Shen Z
    Front Med (Lausanne); 2021; 8():759568. PubMed ID: 34938746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Brownstone ND; Thibodeaux QG; Reddy VD; Myers BA; Chan SY; Bhutani T; Liao W
    Dermatol Ther (Heidelb); 2020 Aug; 10(4):881-885. PubMed ID: 32468230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe Acute Respiratory Syndrome Coronavirus 2 and the Use of Biologics in Patients With Psoriasis [Formula: see text].
    Ladda M; Lynde C; Fleming P
    J Cutan Med Surg; 2020; 24(6):625-632. PubMed ID: 32757760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments.
    Gisondi P; Bellinato F; Chiricozzi A; Girolomoni G
    Vaccines (Basel); 2020 Dec; 8(4):. PubMed ID: 33276686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-center survey of biologic use for inflammatory skin diseases during the coronavirus disease 2019 pandemic.
    Kado S; Kamiya K; Kishimoto M; Maekawa T; Kuwahara A; Sugai J; Komine M; Ohtsuki M
    J Dermatol; 2021 Dec; 48(12):1907-1912. PubMed ID: 34549456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of biologics during the COVID-19 pandemic: lessons learned from psoriasis.
    Gisondi P; Geat D; Bellinato F; Girolomoni G
    Expert Opin Biol Ther; 2022 Dec; 22(12):1521-1529. PubMed ID: 35930356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Moderate to Severe Psoriasis during the COVID-19 Pandemic: Lessons Learned and Opportunities.
    Campanati A; Diotallevi F; Martina E; Radi G; Offidani A
    J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical management of psoriasis patients during the COVID-19 pandemic.
    Chat VS; Uppal SK; Kearns DG; Wu JJ
    J Dermatolog Treat; 2022 Mar; 33(2):1166-1167. PubMed ID: 32568009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance of psoriatic patients on biologic treatment during the COVID-19 pandemic: A single-center experience.
    Polat Ekinci A; Pehlivan G; Gökalp MO
    Dermatol Ther; 2021 Jan; 34(1):e14700. PubMed ID: 33369063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.
    Brownstone ND; Thibodeaux QG; Reddy VD; Myers BA; Chan SY; Bhutani T; Liao W
    Dermatol Ther (Heidelb); 2020 Jun; 10(3):339-349. PubMed ID: 32300516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration.
    Damiani G; Pacifico A; Bragazzi NL; Malagoli P
    Dermatol Ther; 2020 Sep; 33(5):e13475. PubMed ID: 32356577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic.
    Rosi E; Fastame MT; Di Cesare A; Silvi G; Pimpinelli N; Prignano F
    J Clin Med; 2021 Dec; 10(24):. PubMed ID: 34945136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approved Biologics: Can Etanercept and Ustekinumab be Considered a First-Line Systemic Therapy for Pediatric/Adolescents in Moderate to Severe Psoriasis? A Systematic Review.
    Aslam N; Saleem H; Murtazaliev S; Quazi SJ; Khan S
    Cureus; 2020 Aug; 12(8):e9812. PubMed ID: 32953323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.
    Wan MT; Shin DB; Winthrop KL; Gelfand JM
    J Am Acad Dermatol; 2020 Aug; 83(2):677-679. PubMed ID: 32416207
    [No Abstract]   [Full Text] [Related]  

  • 17. COVID-19 knowledge prevents biologics discontinuation: Data from an Italian multicenter survey during RED-ZONE declaration.
    Bragazzi NL; Riccò M; Pacifico A; Malagoli P; Kridin K; Pigatto P; Damiani G
    Dermatol Ther; 2020 Jul; 33(4):e13508. PubMed ID: 32415727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review.
    Sadeghinia A; Daneshpazhooh M
    Dermatol Ther; 2021 Jan; 34(1):e14498. PubMed ID: 33141519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)
    Klimek L; Pfaar O; Worm M; Eiwegger T; Hagemann J; Ollert M; Untersmayr E; Hoffmann-Sommergruber K; Vultaggio A; Agache I; Bavbek S; Bossios A; Casper I; Chan S; Chatzipetrou A; Vogelberg C; Firinu D; Kauppi P; Kolios A; Kothari A; Matucci A; Palomares O; Szépfalusi Z; Pohl W; Hötzenecker W; Rosenkranz AR; Bergmann KC; Bieber T; Buhl R; Buters J; Darsow U; Keil T; Kleine-Tebbe J; Lau S; Maurer M; Merk H; Mösges R; Saloga J; Staubach P; Jappe U; Rabe KF; Rabe U; Vogelmeier C; Biedermann T; Jung K; Schlenter W; Ring J; Chaker A; Wehrmann W; Becker S; Freudelsperger L; Mülleneisen N; Nemat K; Czech W; Wrede H; Brehler R; Fuchs T; Tomazic PV; Aberer W; Fink-Wagner AH; Horak F; Wöhrl S; Niederberger-Leppin V; Pali-Schöll I; Pohl W; Roller-Wirnsberger R; Spranger O; Valenta R; Akdis M; Matricardi PM; Spertini F; Khaltaev N; Michel JP; Nicod L; Schmid-Grendelmeier P; Idzko M; Hamelmann E; Jakob T; Werfel T; Wagenmann M; Taube C; Jensen-Jarolim E; Korn S; Hentges F; Schwarze J; O Mahony L; Knol EF; Del Giacco S; Chivato Pérez T; Bousquet J; Bedbrook A; Zuberbier T; Akdis C; Jutel M
    Allergol Select; 2020; 4():53-68. PubMed ID: 32915172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.